Jin Xu

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. ncbi Characterizing exons 11 and 1 promoters of the mu opioid receptor (Oprm) gene in transgenic mice
    Jin Xu
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021 USA
    BMC Mol Biol 7:41. 2006
  2. ncbi Isolation and characterization of new exon 11-associated N-terminal splice variants of the human mu opioid receptor gene
    Jin Xu
    Department of Neurology and The Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    J Neurochem 108:962-72. 2009
  3. ncbi Identification and characterization of seven new exon 11-associated splice variants of the rat μ opioid receptor gene, OPRM1
    Jin Xu
    Department of Neurology and Program in Molecular Pharmacology and Chemistry, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Mol Pain 7:9. 2011
  4. ncbi Identification of three new alternatively spliced variants of the rat mu opioid receptor gene: dissociation of affinity and efficacy
    David A Pasternak
    Laboratory of Molecular Neuropharmacology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Neurochem 91:881-90. 2004
  5. ncbi Identification of four novel exon 5 splice variants of the mouse mu-opioid receptor gene: functional consequences of C-terminal splicing
    Ying Xian Pan
    Laboratory of Molecular Neuropharmacology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    Mol Pharmacol 68:866-75. 2005
  6. ncbi Involvement of exon 11-associated variants of the mu opioid receptor MOR-1 in heroin, but not morphine, actions
    Ying Xian Pan
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Proc Natl Acad Sci U S A 106:4917-22. 2009
  7. ncbi Identification and characterization of two new human mu opioid receptor splice variants, hMOR-1O and hMOR-1X
    Ying Xian Pan
    Department of Neurology, Laboratory of Molecular Neuropharmacology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    Biochem Biophys Res Commun 301:1057-61. 2003
  8. ncbi Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis
    Jennifer C King
    Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Nat Genet 41:524-6. 2009

Collaborators

Detail Information

Publications8

  1. ncbi Characterizing exons 11 and 1 promoters of the mu opioid receptor (Oprm) gene in transgenic mice
    Jin Xu
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021 USA
    BMC Mol Biol 7:41. 2006
    ..The aim of this study is to further characterize the E11 and E1 promoters in vivo using a transgenic mouse model...
  2. ncbi Isolation and characterization of new exon 11-associated N-terminal splice variants of the human mu opioid receptor gene
    Jin Xu
    Department of Neurology and The Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    J Neurochem 108:962-72. 2009
    ..The presence of exon 11-associated variants in humans raises questions regarding their potential role in heroin and morphine-6beta-glucuronide actions in people as they do in mice...
  3. ncbi Identification and characterization of seven new exon 11-associated splice variants of the rat μ opioid receptor gene, OPRM1
    Jin Xu
    Department of Neurology and Program in Molecular Pharmacology and Chemistry, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Mol Pain 7:9. 2011
    ..We now have examined 5' splicing in the rat...
  4. ncbi Identification of three new alternatively spliced variants of the rat mu opioid receptor gene: dissociation of affinity and efficacy
    David A Pasternak
    Laboratory of Molecular Neuropharmacology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Neurochem 91:881-90. 2004
    ..Thus, selectivity of opioid action might be achieved by designing compounds with varying efficacies at different MOR-1 variants...
  5. ncbi Identification of four novel exon 5 splice variants of the mouse mu-opioid receptor gene: functional consequences of C-terminal splicing
    Ying Xian Pan
    Laboratory of Molecular Neuropharmacology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    Mol Pharmacol 68:866-75. 2005
    ..In conclusion, alterations in the amino acid sequence of the C terminus do not alter the mu-specificity of the receptor but they can influence the binding characteristics, efficacy, and potency of mu-opioids...
  6. ncbi Involvement of exon 11-associated variants of the mu opioid receptor MOR-1 in heroin, but not morphine, actions
    Ying Xian Pan
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Proc Natl Acad Sci U S A 106:4917-22. 2009
    ....
  7. ncbi Identification and characterization of two new human mu opioid receptor splice variants, hMOR-1O and hMOR-1X
    Ying Xian Pan
    Department of Neurology, Laboratory of Molecular Neuropharmacology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    Biochem Biophys Res Commun 301:1057-61. 2003
    ..These two new human mu opioid receptors are the first human MOR-1 variants containing new exons and suggest that the complex splicing present in mice may extend to humans...
  8. ncbi Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis
    Jennifer C King
    Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Nat Genet 41:524-6. 2009
    ..TMPRSS2-ERG-positive human tumors are also enriched for PTEN loss, suggesting cooperation in prostate tumorigenesis...